How Safe Is Amgen's Dividend?
(NASDAQ: AMGN) has been grabbing headlines lately, and not always for the right reasons. The company is currently engaged in a battle with the U.S. Food and Drug Administration (FDA), which has demanded that the biotech pull Tavneos, a medicine for severe anti-neutrophil cytoplasmic autoantibody-associated vasculitis (a group of rare autoimmune inflammatory diseases), from the market. The FDA is claiming that Amgen manipulated clinical trial data.
Elsewhere, Amgen has been fighting off attempts by Colorado regulators to cap the annual price of its famous psoriatic arthritis drug, Enbrel. Amgen recently won a court victory in that battle, although it probably isn't completely over yet. With all that going on, some might worry about Amgen's business and ability to maintain its dividend program intact. Should investors seek out other dividend stocks?
Image source: The Motley Fool.
Source Fool.com
Amgen Inc. Aktie
Deutliches Buy-Überwiegen bei Amgen Inc. im Vergleich zu Sell-Einschätzungen.
Trotz eines Kursziels von 332 €, das unter 334.1 € liegt, ergibt sich für Amgen Inc. ein negatives Potenzial von -0.63%.
